Skip to main content

Table 3 Toxicity

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Hematological Toxicity

Gr1

Gr2

Gr3

Gr4

Gr3 (%)

Over all (%)

anemia

0

11

0

0

0 (0)

11 (26.2)

leukopenia

0

1

0

0

1 (0)

1 (2.3)

thrombocytopenia

0

2

3

0

3 (7.1)

5 (11.9)

Non-hematological Toxicity

Gr1

Gr2

Gr3

Gr4

Gr3 (%)

Over all (%)

nausea

3

4

1

0

1 (2.3)

8 (19.0)

vomiting

1

1

3

0

1 (2.3)

5 (11.9)

appetite loss

0

0

6

0

6 (14.3)

6 (14.3)

oral mucositis

0

4

0

0

0 (0)

4 (9.5)

taste disturbance

0

1

0

0

1 (2.3)

1 (2.3)

upper GI tract bleeding

0

1

0

0

0 (0)

1 (2.3)

diarrhea

1

0

0

0

0 (0)

1 (2.3)

general fatigue

0

1

1

0

1 (2.3)

2 (4.7)

jaundice

0

0

4

0

4 (9.5)

4 (9.5)

serum AST/ALT level elevation

0

4

1

0

1 (2.3)

1 (2.3)

Serum creatinine level elevation

0

6

0

0

0 (0)

6 (14.3)